Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460483 · ClinicalTrials.gov registry record · NA
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 1,001
- Enrollment target
NCT03460483 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 1,001 participants.
The verdict
NCT03460483, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,001 participants
- Enrollment target
Study Summary
This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Genetic Testing
- OTHER Genetic Counseling
- PROCEDURE Mutation Carrier Screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,001 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2025-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03460483
The ClinicalTrials.gov registry entry for NCT03460483 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,001 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03460483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03460483 about?
NCT03460483 is a clinical study titled "Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care". This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strateg...
What is the current status of trial NCT03460483?
This trial is currently completed. It is a NA study. The enrollment target is 1,001 participants. The study started on 2018-03-30. Estimated completion is 2025-06-15.
What interventions are being tested in trial NCT03460483?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Genetic Testing (OTHER), Genetic Counseling (OTHER), Mutation Carrier Screening (PROCEDURE).
Who is sponsoring clinical trial NCT03460483?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.